Buy Tesamorelin for Sale
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone. It was initially developed as a potential treatment for lipodystrophy, a group of conditions characterized by abnormal fat distribution throughout the body.
Clinical research suggests that Tesamorelin could reduce visceral adipose tissue in patients with HIV. It is currently being researched for its ability to lower triglyceride levels, improve body composition, and slow the progression of mild cognitive impairment.
What is Tesamorelin?
Tesamorelin is an analog of the growth hormone-releasing hormone (GHRH) that stimulates the production of GH from the pituitary gland. It has also been found to induce a dose-dependent increase in insulin-like growth factor 1 (IGF-1) levels in the body. [R]
Tesamorelin was developed by a Canada-based pharmaceutical company as a potential treatment for lipodystrophy. Lipodystrophy is a condition in which a person loses fat in some parts of the body while gaining it in others. It is common in HIV-infected patients. [R]
In 2010, the FDA approved Tesamorelin as a treatment for HIV-related lipodystrophy. This approval was based on results obtained from two trials. In both trials, Tesamorelin treatment reduced excess abdominal fat associated with lipodystrophy in HIV-infected patients. [R]
Clinical research suggests that Tesamorelin could lower triglyceride levels (therefore boosting heart health) in people with HIV. Additionally, it has been found to improve cognitive function and short-term verbal memory in patients with mild cognitive impairment. [R]
How Does Tesamorelin Work?
Tesamorelin works by mimicking the effects of GHRH in the body. It binds to GHRH receptors on the surface of the pituitary, which triggers the release of GH. The GH has been shown to decrease the amount of body fat. Its reduced levels are associated with HIV-associated dystrophy.
Tesamorelin has also been found to induce a dose-related increase in IGF-1 secretion from the hypothalamus, which is where the pituitary is located. IGF-1 plays several crucial functions in the body, including lowering blood glucose levels while suppressing insulin production. [R]
Multiple clinical and preclinical studies have examined the potential effects of this synthetic growth hormone-releasing factor (GRF). Here are the key findings:
1) Tesamorelin and Lipodystrophy
Lipodystrophy is common in HIV patients undergoing antiretroviral therapy (ART). It targets the face, arms, legs, buttocks, and truncal areas.
The FDA has approved Tesamorelin as a treatment for HIV-associated lipodystrophy. The approval was granted in November 2010 based on results from two Phase 3 multi-center trials. [R]
Both trials showed statistically significant reductions in visceral adipose tissue and waist circumferences in HIV-infected patients treated with Tesamorelin. The increase in VAT and waist size is a common feature of HIV-associated lipodystrophy in patients receiving ART. [R]
2) Tesamorelin and Cardiovascular Disease
Tesamorelin may reduce various CVD risk factors.
In a placebo-controlled trial involving obese subjects with reduced GH levels, Tesamorelin selectively reduced the levels of triglycerides, C-reactive protein, and thickness of carotid artery walls. The elevation of all these indices increases your risk of developing CVD. [R]
Another human study showed that Tesamorelin treatment successfully reduced triglyceride levels in HIV patients, who are at an added risk of developing cardiovascular disease. It also significantly improved total and HDL (or ‘good’) cholesterol levels in the test subjects. [R]
3) Tesamorelin and NAFLD
Non-alcoholic fatty liver disease refers to excess fat buildup in the liver. An estimated 30 to 65% of persons with HIV infections are affected by NAFLD.
Preclinical research shows that Tesamorelin could inhibit various pathways linked to HIV-associated NAFLD. This synthetic peptide has been found to reduce liver fat and prevent fibrosis progression in HIV-associated NAFLD. It can also suppress genes involved in liver inflammation. [R]
A human trial reports that Tesamorelin treatment reduced hepatic fat function (HPP) levels in HIV patients with NAFLD. Around 35% of treated test subjects experienced this improvement. This is significant as increased HFF levels contribute to the development and progression of NAFLD. [R]
4) Tesamorelin and Cognitive Function
Clinical research shows that Tesamorelin may improve cognitive function.
In a clinical study, this synthetic peptide positively affected executive function and short-term memory. The trial comprised healthy older adults as well as those with mild cognitive impairment (MCI). Both groups experienced improvements in cognitive function. [R]
Another study reported that short-term Tesamorelin administration improves executive function for healthy and memory-impaired older adults. Additionally, this synthetic peptide exerted a positive effect on verbal memory for adults with AI who are at high risk of Alzheimer’s. [R]
5) Tesamorelin and Obesity
Tesamorelin may be beneficial for people living with obesity.
In a randomized, placebo-controlled trial, this synthetic peptide selectively reduced VAT without significant effects on adipose tissue. Additionally, it improved the subjects’ triglyceride and C-reactive protein levels, which are often elevated by obesity. [R]
Another trial showed that Tesamorelin reduced abdominal adiposity in viscerally obese subjects with HIV lipodystrophy. Abdominal adiposity refers to the accumulation of fat in the abdominal area. It is more commonly referred to as “belly fat.” [R]
6) Tesamorelin and Sarcopenia
A placebo-controlled trial showed that Tesamorelin may be beneficial for sarcopenia.
The trial was conducted on HIV-positive patients living with abdominal obesity. Its goal was to determine the effects of Tesamorelin peptide on muscle quality (density) and quantity (area). [R]
Results from the trial show that Tesamorelin treatment significantly increased skeletal muscle mass and reduced fat mass. It also improved skeletal muscle area and density. All these changes were observed in those patients with significant decreases in visceral adipose tissue. [R]
7) Tesamorelin and Peripheral Nerve Injury
Peripheral nerve injury refers to the damage of nerves located outside of the brain and spinal cord. A physical injury or medical condition can cause it.
Tesamorelin is undergoing phase 2 clinical trials as a potential therapy for peripheral nerve injuries. The investigators hypothesize that treatment with this synthetic peptide will allow for greater and faster recovery of motor and sensory function following surgery. [R]
8) Tesamorelin and COPD
Chronic Obstructive Pulmonary disease refers to a group of diseases that cause airflow blockage and breathing-related problems.
In a multi-center, double-blind, placebo-controlled trial, Tesamorelin improved body composition in COBD patients by increasing lean mass. The research chemical was also reported to improve limb and respiratory muscle strength in research subjects. [R] [R] [R]
Where to Buy Tesamorelin for Sale?
ResearchChems.org is the best place to buy Tesamorelin online.
We have been around since 2023, supplying the highest-quality research chemicals money can buy. Our products come with a 100% satisfaction guarantee, fast shipping, and great customer service to turn every customer into a repeat customer.
Tesamorelin is a GHRH analog that is clinically used to treat HIV-associated lipodystrophy. In clinical studies, it has demonstrated the ability to enhance cognitive function, suppress various cardiovascular disease risk factors, and reduce the severity of NAFLD in people living with HIV infection.
ResearchChems.org sells Tesamorelin for laboratory and research use, not human consumption.